Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Altea, Hospira To Develop Transdermal Product | Contract Pharma

What are you searching for?

Sign in
Breaking News

Altea, Hospira To Develop Transdermal Product

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Altea Therapeutics has entered into a partnership with Hospira for the development and commercialization of an undisclosed product using its PassPort Transdermal Delivery System. Under the terms of the agreement, Hospira has exclusive worldwide rights to develop and commercialize the product. Altea will fund certain Phase I studies and Hospira will fund all further product development, manufacturing, and commercialization. Altea will receive an upfront payment, which includes an equity investment. Altea could receive milestone payments of as much as $109 million and royalties on sales of the product over the term of the agreement.
   
“This agreement further validates the development of the Altea Therapeutics transdermal patch technology for drugs that previously were administered by needle injection or infusion, including water-soluble proteins, carbohydrates, and small drugs,” said Dr. Eric Tomlinson, president and chief executive officer of Altea. “Based on our existing relationship with Hospira, we believe they are the ideal partner with the technological and scientific expertise, and the global commercial reach necessary to develop and commercialize this product.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters